Deloitte Showcases Family of Products for Health Care Providers and Announces Launch of Care Intellect

ORLANDO, Fla., June 26, 2017 -This year at the HFMA Annual National Institute, Deloitte will be showcasing its suite of provider margin improvement analytics services and products. This family of products for health care providers includes the ConvergeHEALTH Provider Intellect suite and LaborWise, Deloitte's workforce-focused analytics solution that identifies labor overspend. Deloitte is launching Care Intellect™, a provider performance improvement analytics solution that is designed to deliver higher-value care by managing variations across patient encounters, integrating leading evidence-based practices to improve patient outcomes and discover related cost-saving opportunities. The team and tools gather information and insights on clinical costs and domain-level drivers of variation and then incorporates the new information into Care Intellect. The solution applies cognitive analytics to drive deeper insights to inform decision-making for the redesign teams. "The pairing of encounter-level data for use by leadership with the construction of multidisciplinary care teams provides a laser focus to understand both where variation exists and its impact on outcomes," said Dede Hartung, managing director, Deloitte Consulting LLP, and clinical efficiency effectiveness solution national leader. "Clinical-friendly, flexible tools that extract timely, meaningful information from complex data sets allows for hypothesis-generating inquiries. This in turn supports care redesign across diagnoses and populations. This solution, coupled with services from Deloitte's clinical effectiveness practice, enables clients to continue the transition from focus on volume to value-based care." "Collaborating with Deloitte helped us to move our care delivery redesign work further and faster," said Dr. George R. Cheely Jr., MBA, assistant professor of medicine, hospital medicine, Duke University Hospital. "They brought a team adept at coaching physicians to improve patient outcomes and reduce cost. Working together allowed us to have more hands on deck at a time of rapid change. Our organization has seen measurable benefits, but more importantly, we've elevated the care of our patients to even greater heights." Care Intellect is the latest addition to the Provider Intellect product suite of health care margin improvement products offered by Deloitte that will be exhibited at HFMA ANI the week of June 26 in Orlando: · Revenue Intellect™ is a cloud-based, guided-analytics platform that is designed to help maximize and sustain financial margin through revenue cycle performance. Revenue Intellect enables users to identify hidden or hard-to-find sources of revenue loss and access data, ranging from targeted analyses to free-form data exploration, to provide value to all levels of a health care provider's operational structure.· Cost Intellect™ uses both structured and unstructured data from a variety of sources including enterprise resource planning (ERP)/financial data, electronic medical record (EMR)/clinical data, raw data storage (Data Lake) and other miscellaneous files. The solution integrates information in a highly-scalable, easily configured platform, providing the insights and analytics that improve the way costs are measured and reported.· LaborWise™ is Deloitte's workforce-focused analytics solution that identifies, quantifies and unlocks hidden sources of labor overspend, empowering organizations to optimize their workforce, drive sustainable savings and improve productivity. "Health care providers are being challenged more than ever to deliver value-based care under increasing cost constraints. In today's health care environment, providers need to implement strategies and solutions that put patients first but also enable them to focus on the cost of operating their facilities," said Chip Newton, senior manager, Deloitte Consulting LLP and product leader for LaborWise.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.